タンパク質間相互作用を検出するためのグラフェンバイオセンサベースの電界効果バイオセンシング

Executive Industry Relevance

Field-effect biosensing using graphene transistors enables label-free, real-time detection of protein-protein interactions, supporting early-stage target validation in drug discovery. By quantifying binding affinity through electrical readouts, the method provides predictive confidence for therapeutic hypothesis de-risking. This approach addresses the need for reproducible, quantitative assays in preclinical target engagement studies.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by measuring binding kinetics between target proteins like Hsp90 and client proteins such as Cdc37.
• Operational Value: Provides quantitative I-response data that supports functional target validation and pathway clarification.
• Predictive Value: Generates dose-dependent binding curves to inform lead identification and portfolio triage decisions.

Screening & Assay Development

• Assay Readiness: Produces standardized, regenerable sensor surfaces suitable for screening compound effects on protein interactions.
• Quantitative Output: Delivers concentration-dependent electrical signals enabling KD determination and hit confirmation.
• Platform Reuse: Supports repeated cycles of association, dissociation, and regeneration for scalable assay implementation.

Translational & Preclinical Research

• Translational Continuity: Bridges discovery-phase interaction data with preclinical models by validating target engagement in disease-relevant systems.
• Mechanistic De-risking: Clarifies Hsp90-Cdc37 interaction dynamics, reducing uncertainty in downstream biomarker and efficacy studies.
• Risk-Adjusted Advancement: Informs go/no-go decisions based on reproducible binding affinity measurements.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead optimization, enabling iterative assessment of molecular interactions that influence compound selection.

• Discovery Biology: Supports hypothesis testing by detecting and quantifying specific protein-protein interactions in controlled buffer conditions.
• Screening: Delivers reproducible, label-free readouts that facilitate compound screening against PPI targets.
• Analytics: Generates real-time current response (I-response) measurements that quantify binding affinity and kinetics.
• Translational Research: Connects molecular interaction data to preclinical continuity by confirming target engagement in physiologically relevant contexts.
• Enterprise Reuse: Establishes a regenerable biosensor platform applicable across multiple target classes and projects.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation through direct, quantitative measurement of binding events.
• Operational Value: Ensures assay standardization and reproducibility via immobilized protein surfaces and regeneration cycles.
• Strategic Value: Improves capital efficiency by reducing late-stage failure risk through early mechanistic de-risking.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on validated interaction strength and druggability.

Implementation Considerations

• Requires expertise in protein chemistry, surface functionalization, and electrochemical measurement techniques.
• Depends on access to graphene field-effect transistor instrumentation and fluidic control systems.
• Necessitates standardization of immobilization, quenching, and regeneration protocols across teams.
• Involves adaptation considerations for different protein pairs, buffer conditions, and analyte solubility profiles.
• Includes practical limitations such as surface fouling over cycles and the need for optimized surface density to avoid mass transport effects.

Biopharma FAQs